Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.
Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease
Posted inGeneral Surgery news Oncology

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

A comprehensive meta-analysis suggests that for intermediate-risk papillary thyroid carcinoma with unilateral lateral lymph node metastasis, lobectomy provides oncological outcomes comparable to total thyroidectomy, challenging the necessity of radical resection and adjuvant radioactive iodine in this cohort.
Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
Posted inHematology-Oncology news Oncology

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surveillance alone, offering a scalable model for population-level symptom management.